EP4306166A3 - Compounds, compositions and methods of use - Google Patents

Compounds, compositions and methods of use Download PDF

Info

Publication number
EP4306166A3
EP4306166A3 EP23191374.0A EP23191374A EP4306166A3 EP 4306166 A3 EP4306166 A3 EP 4306166A3 EP 23191374 A EP23191374 A EP 23191374A EP 4306166 A3 EP4306166 A3 EP 4306166A3
Authority
EP
European Patent Office
Prior art keywords
compositions
compounds
methods
diseases
onset
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP23191374.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4306166A2 (en
Inventor
Duane A. Burnett
Joseph P. Vacca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aquinnah Pharmaceuticals Inc
Original Assignee
Aquinnah Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aquinnah Pharmaceuticals Inc filed Critical Aquinnah Pharmaceuticals Inc
Publication of EP4306166A2 publication Critical patent/EP4306166A2/en
Publication of EP4306166A3 publication Critical patent/EP4306166A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/79—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
EP23191374.0A 2016-12-23 2017-12-22 Compounds, compositions and methods of use Withdrawn EP4306166A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662438836P 2016-12-23 2016-12-23
US201762560493P 2017-09-19 2017-09-19
EP17883239.0A EP3557998B1 (en) 2016-12-23 2017-12-22 Compouns, compositions and methods of use
PCT/US2017/068186 WO2018119395A1 (en) 2016-12-23 2017-12-22 Compouns, compositions and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP17883239.0A Division EP3557998B1 (en) 2016-12-23 2017-12-22 Compouns, compositions and methods of use

Publications (2)

Publication Number Publication Date
EP4306166A2 EP4306166A2 (en) 2024-01-17
EP4306166A3 true EP4306166A3 (en) 2024-06-26

Family

ID=62627194

Family Applications (2)

Application Number Title Priority Date Filing Date
EP17883239.0A Active EP3557998B1 (en) 2016-12-23 2017-12-22 Compouns, compositions and methods of use
EP23191374.0A Withdrawn EP4306166A3 (en) 2016-12-23 2017-12-22 Compounds, compositions and methods of use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP17883239.0A Active EP3557998B1 (en) 2016-12-23 2017-12-22 Compouns, compositions and methods of use

Country Status (10)

Country Link
US (2) US11542233B2 (da)
EP (2) EP3557998B1 (da)
JP (2) JP7299837B2 (da)
AU (1) AU2017382360B2 (da)
CA (1) CA3047404A1 (da)
DK (1) DK3557998T3 (da)
ES (1) ES2968227T3 (da)
HU (1) HUE065438T2 (da)
PL (1) PL3557998T3 (da)
WO (1) WO2018119395A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017382360B2 (en) * 2016-12-23 2022-07-28 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
US11993571B2 (en) * 2017-03-10 2024-05-28 Rutgers, The State University Of New Jersey Indole derivatives as efflux pump inhibitors
IL274406B2 (en) * 2017-11-02 2024-04-01 Calico Life Sciences Llc Combined pressure pathway modulators
EP3704115A1 (en) 2017-11-02 2020-09-09 Calico Life Sciences LLC Modulators of the integrated stress pathway
US11453676B2 (en) 2018-02-02 2022-09-27 Forward Therapeutics, Inc. Inhibitors of protein arginine deiminases
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
MX2022004390A (es) 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
EP4173675A1 (en) * 2021-10-26 2023-05-03 Perha Pharmaceuticals Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
WO2025175249A1 (en) 2024-02-14 2025-08-21 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1403255A1 (en) * 2001-06-12 2004-03-31 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
EP1739084A1 (fr) * 2005-06-29 2007-01-03 L'oreal Para-phénylènediamines doubles reliées par un bras de liaison comportant un radical cyclique saturé et utilisation en coloration
WO2009153720A1 (en) * 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
WO2012162249A1 (en) * 2011-05-20 2012-11-29 Benjamin Wolozin Identification of compounds that disperse tdp-43 inclusions

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5455262A (en) * 1993-10-06 1995-10-03 Florida State University Mercaptosulfide metalloproteinase inhibitors
AU770042B2 (en) * 1998-12-18 2004-02-12 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000047194A2 (en) * 1999-02-09 2000-08-17 3-Dimensional Pharmaceuticals, Inc. METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
AU7353300A (en) 1999-09-08 2001-04-10 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
US6743794B2 (en) 1999-12-22 2004-06-01 Eli Lilly And Company Methods and compounds for inhibiting MRP1
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SI2527315T1 (sl) 2002-05-31 2014-06-30 Proteotech Inc., Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
SE0202134D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
JP2005213194A (ja) 2004-01-29 2005-08-11 Mitsui Chemicals Inc ポリフェノール類を含有する抗菌剤
WO2006040646A1 (en) * 2004-10-14 2006-04-20 Pfizer, Inc. Benzimidazole or indole amides as inhibitors of pin1
US20090054392A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
US8211872B1 (en) * 2007-10-24 2012-07-03 MedDEV, Inc. Method and composition for treatment of multiple sclerosis and related neurodegenerative conditions
EP2367545A1 (en) 2008-10-17 2011-09-28 Université Libre de Bruxelles Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy
PH12015501678B1 (en) * 2009-06-17 2022-07-06 Vertex Pharma Inhibitors of influenza viruses replication
KR101271223B1 (ko) 2011-01-27 2013-06-07 한국과학기술연구원 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제
KR20150113195A (ko) 2013-03-05 2015-10-07 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2944669A1 (en) * 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016020526A1 (en) * 2014-08-08 2016-02-11 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
KR102531340B1 (ko) 2014-09-08 2023-05-10 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 인플루엔자 바이러스 감염에 사용하기 위한 피롤로피리미딘
WO2016040780A1 (en) 2014-09-11 2016-03-17 Neuropore Therapies, Inc. Aminomethyl- and methyloxy-linked tricyclic compounds as inhibitors of protein aggregation
WO2016058544A1 (en) 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10870651B2 (en) * 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP6947651B2 (ja) * 2015-06-26 2021-10-13 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ４，６−ピリミジニレン誘導体およびこれらの使用
ES2854703T3 (es) * 2015-07-09 2021-09-22 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de BTK y usos de los mismos
US10626108B2 (en) * 2015-11-27 2020-04-21 Janssen Sciences Ireland Uc Heterocyclic indoles for use in influenza virus infection
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
AU2017382360B2 (en) 2016-12-23 2022-07-28 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1403255A1 (en) * 2001-06-12 2004-03-31 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
EP1739084A1 (fr) * 2005-06-29 2007-01-03 L'oreal Para-phénylènediamines doubles reliées par un bras de liaison comportant un radical cyclique saturé et utilisation en coloration
WO2009153720A1 (en) * 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
WO2012162249A1 (en) * 2011-05-20 2012-11-29 Benjamin Wolozin Identification of compounds that disperse tdp-43 inclusions

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BARBARA BUCHS (NÉE LEVRAND) ET AL: "Reversible Aminal Formation: Controlling the Evaporation of Bioactive Volatiles by Dynamic Combinatorial/Covalent Chemistry", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, WILEY-VCH, DE, vol. 2011, no. 4, 28 December 2010 (2010-12-28), pages 681 - 695, XP072116072, ISSN: 1434-193X, DOI: 10.1002/EJOC.201001433 *
CATTO MARCO ET AL: "Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 21, no. 1, 7 November 2012 (2012-11-07), pages 146 - 152, XP028961392, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2012.10.045 *
CHUNQUAN SHENG ET AL: "Homology modeling and molecular dynamics simulation of N-myristoyltransferase from protozoan parasites: active site characterization and insights into rational inhibitor design", JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, KLUWER ACADEMIC PUBLISHERS, DO, vol. 23, no. 6, 16 April 2009 (2009-04-16), pages 375 - 389, XP019678501, ISSN: 1573-4951 *
DERUN LI ET AL: "Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists", ACS MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 6, 25 April 2014 (2014-04-25), US, pages 690 - 695, XP055736942, ISSN: 1948-5875, DOI: 10.1021/ml500079u *
GOULET S ET AL: "Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 20, no. 1, 1 January 2010 (2010-01-01), pages 196 - 200, XP026808804, ISSN: 0960-894X, [retrieved on 20091104] *
YAMAZAKI K ET AL: "Synthesis of potent and selective inhibitors of Candida albicans N-myristoyltransferase based on the benzothiazole structure", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 13, no. 7, 1 April 2005 (2005-04-01), pages 2509 - 2522, XP027637609, ISSN: 0968-0896, [retrieved on 20050401] *
ZHONGXING ZHANG ET AL: "Selective Monoacylation of Symmetrical Diamines via Prior Complexation with Boron", ORGANIC LETTERS, vol. 5, no. 19, 1 September 2003 (2003-09-01), pages 3399 - 3402, XP055103697, ISSN: 1523-7060, DOI: 10.1021/ol0300773 *
ZHOU HAO ET AL: "Discovery and structure-activity relationship of 1,3-cyclohexyl amide derivatives as novel mGluR5 negative allosteric modulators", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 23, no. 5, 5 January 2013 (2013-01-05), pages 1398 - 1406, XP028976436, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2012.12.078 *

Also Published As

Publication number Publication date
JP7299837B2 (ja) 2023-06-28
PL3557998T3 (pl) 2024-03-11
US11542233B2 (en) 2023-01-03
EP4306166A2 (en) 2024-01-17
HUE065438T2 (hu) 2024-05-28
JP2020503314A (ja) 2020-01-30
CA3047404A1 (en) 2018-06-28
WO2018119395A1 (en) 2018-06-28
JP2023033357A (ja) 2023-03-10
US20230303489A1 (en) 2023-09-28
WO2018119395A8 (en) 2019-05-23
ES2968227T3 (es) 2024-05-08
EP3557998B1 (en) 2023-08-16
EP3557998A1 (en) 2019-10-30
AU2017382360A1 (en) 2019-07-04
DK3557998T3 (da) 2023-11-20
EP3557998A4 (en) 2020-12-02
US20200270211A1 (en) 2020-08-27
AU2017382360B2 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
EP4306166A3 (en) Compounds, compositions and methods of use
ZA202004557B (en) Modulatory polynucleotides
PH12018502429A1 (en) Antibody molecules for cancer treatment
EP3603661A3 (en) Rna containing composition for treatment of tumor diseases
MX2023010042A (es) Polinucleotidos moduladores.
AU2017319323A8 (en) Biaryl compounds useful as immunomodulators
PH12017500803A1 (en) Anti-pd-1 antibodies
EP4620519A3 (en) Methods and compositions relating to chondrisomes from blood products
EP4230627A3 (en) Inhibitors of the menin-mll interaction
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
MY187540A (en) Compounds active towards bromodomains
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
AU2015237050A8 (en) Quinoline derivatives as SMO inhibitors
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MY192927A (en) Fused bicyclic compounds for the treatment of disease
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
WO2015184257A3 (en) Small molecule transcription modulators of bromodomains
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
EP3229793A4 (en) Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3557998

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0025000000

Ipc: C07C0233790000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/16 20060101ALI20240521BHEP

Ipc: C07D 491/048 20060101ALI20240521BHEP

Ipc: C07D 471/04 20060101ALI20240521BHEP

Ipc: C07D 417/12 20060101ALI20240521BHEP

Ipc: C07D 413/12 20060101ALI20240521BHEP

Ipc: C07D 409/12 20060101ALI20240521BHEP

Ipc: C07D 405/12 20060101ALI20240521BHEP

Ipc: C07D 403/12 20060101ALI20240521BHEP

Ipc: C07D 401/12 20060101ALI20240521BHEP

Ipc: C07D 235/24 20060101ALI20240521BHEP

Ipc: C07D 213/81 20060101ALI20240521BHEP

Ipc: C07D 209/42 20060101ALI20240521BHEP

Ipc: C07C 233/79 20060101AFI20240521BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20250103